Table 3.

Evidence Gaps Regarding Statins for Primary Prevention in Adults Aged 75 and Older Without Atherosclerotic Cardiovascular Disease

Characteristics	Area Requiring New Clinical Trial Evidence
Patient groups	• Larger numbers of older adults, especially aged ≥80, with characteristics representative of the target U.S. population (e.g., multimorbidity, at risk for functional or cognitive decline, polypharmacy) • Data in older women • Data in underrepresented subpopulations such as minorities
Inclusion of measures important to older adults	• Universal health outcomes • Measures of cognition, function, heath-related quality of life, frailty, multiple chronic condition burden, disability, incident dementia, and atherosclerotic cardiovascular disease
Time to benefit	• Data on optimal time to start or stop statin therapy
Specific statin	• Dose and type of statin based on individualized risk assessment